Brief: Poolbeg Pharma Entered Into Exclusive 12-Month Option Agreement With Silk Road Therapeutics
April 30 (Reuters) - Poolbeg Pharma PLC POLB.L :
* OPTION AGREEMENT TO ACQUIRE ORPHAN DRUG CANDIDATE
* EXCLUSIVE OPTION AGREEMENT TO ACQUIRE ORPHAN DRUG
CANDIDATE FOR
BEHÇET'S DISEASE
* ENTERED INTO AN EXCLUSIVE 12-MONTH OPTION AGREEMENT WITH
SILK
ROAD THERAPEUTICS
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Poolbeg Pharma
See all newsBrief: Poolbeg Pharma Says European Patent Granted For POLB 001 In CRS
PDMR Notification
Brief: Poolbeg Pharma Says FDA Feedback Broadly Aligned With Development Pathway For POLB 001
Brief: Poolbeg Pharma Announces Granted POLB 001 Cancer Immunotherapy-Induced CRS Patent In Canada
Annual Report & AGM Notice